ArticleAnalytical and bioanalytical chemistry2025
SERS and colorimetric dual-mode detection of cholesterol during drug treatment of atherosclerosis.
Article in Analytical and bioanalytical chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Fluorescence nanozyme B-CDs@SiOAnalytical and bioanalytical chemistry · 2026Article
- Application of surface-enhanced Raman scattering combined with artificial intelligence for multiplex detection of chemotherapeutic agents used in solid tumors.Analytical and bioanalytical chemistry · 2025Article
- SERS-powered precision: revolutionizing therapeutic drug monitoring with nanoscale sensitivity.Mikrochimica acta · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Foam cell formation caused by cholesterol accumulation in macrophages is an early warning of atherosclerosis. Therefore, in situ and accurate determination of intracellular and extracellular cholesterol in macrophages is of great significance for the early diagnosis of atherosclerosis and the evaluation of its therapeutic effect. Herein, a surface-enhanced Raman spectroscopy (SERS) and colorimetric dual-response plasmonic nano-sensing system was established based on a double-enzyme cascade catalytic reaction to accurately monitor the changes in cholesterol levels during the occurrence and development of atherosclerosis. Cholesterol oxidase modified on gold nanoparticles can catalyze the oxidation of cholesterol to hydrogen peroxide, which oxidizes 3,3,5,5-tetramethylbenzidine (TMB) to oxidation state TMB (oxTMB) under the catalysis of horseradish peroxidase (HRP). The oxTMB showed a very strong SERS signal under the effect of plasmonic enhancement of gold nanoparticles, and the solution of oxTMB is bright blue compared to colorless TMB. Therefore, the dual-response sensing of cholesterol was realized by monitoring SERS and UV absorption signals of the final product oxTMB. Our results suggest that the free cholesterol in macrophages increases after the treatment of avasimibe, which ultimately leads to apoptosis of macrophages. Another drug, high-density lipoprotein, promoted the efflux of intracellular cholesterol and inhibited the foaming of macrophages, thus delaying the development of atherosclerosis. The colorimetric and SERS double-response plasmonic nanosensor realized highly sensitive, specific, and accurate monitoring of intracellular and extracellular cholesterol levels during drug treatment of atherosclerosis. It is expected to provide an effective tool and methodological reference for the prevention and diagnosis of atherosclerosis and a series of cardiovascular diseases related to cholesterol.
Indexed as
Identifiers
40405051What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.